Compare RITM & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RITM | NUVL |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 7.1B |
| IPO Year | N/A | 2021 |
| Metric | RITM | NUVL |
|---|---|---|
| Price | $11.96 | $111.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | $14.22 | ★ $135.00 |
| AVG Volume (30 Days) | ★ 8.0M | 509.2K |
| Earning Date | 01-30-2026 | 02-26-2026 |
| Dividend Yield | ★ 8.51% | N/A |
| EPS Growth | ★ 46.96 | N/A |
| EPS | ★ 1.45 | N/A |
| Revenue | ★ $3,961,432,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.71 | N/A |
| P/E Ratio | $8.10 | ★ N/A |
| Revenue Growth | ★ 32.03 | N/A |
| 52 Week Low | $9.13 | $55.54 |
| 52 Week High | $12.74 | $112.88 |
| Indicator | RITM | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 67.33 | 61.08 |
| Support Level | $11.05 | $101.25 |
| Resistance Level | $11.81 | $108.65 |
| Average True Range (ATR) | 0.25 | 5.53 |
| MACD | 0.07 | 0.90 |
| Stochastic Oscillator | 92.15 | 91.35 |
Rithm Capital Corp operates as a real estate investment trust that provides capital and services to the real estate and financial services industries. The company aims to generate attractive risk-adjusted returns in all interest-rate environments through a complementary portfolio of investments and operating businesses. Its investment portfolio is composed of mortgage servicing-related assets (full and excess MSRs and servicer advances), residential securities (and associated call rights) loans (including single-family rental), and consumer loans. Its operating segments are Origination and Servicing; Investment Portfolio; Residential Transitional Lending; and Asset Management.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.